Diabetes & vascular disease researchDec 29, 2020

Effects of diabetes drugs on type 2 patients with kidney problems

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Mar 29, 2026

Abstract

and systolic blood pressure significantly decreased in both treatment groups after 36 months.

Both GLP-1 receptor agonist and SGLT-2 inhibitors were associated with significant reductions in HbA1c levels.
Systolic blood pressure decreased significantly in both groups over the 36-month period.
Estimated glomerular filtration rate showed a decrease, but this change was not statistically significant.
decreased significantly in both groups, with a subsequent increase observed after 30 months in the SGLT-2 inhibitor group.
Improvements in diastolic cardiac function, measured by specific cardiac indices, were noted only in the GLP-1 receptor agonist group at 36 months.

Simplified

INTRODUCTION: Diabetes mellitus is a progressive disease with cardiovascular complications. We evaluated the impact of a glucagon like peptide-1 (GLP-1) receptor agonist and sodium glucose cotransporter 2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on renal and cardiac function in type 2 diabetes patients with renal impairment.

MATERIALS AND METHODS: A total of 156 patients referred with suboptimal glycemic control were assigned to Group G (GLP-1):= 72 or Group S (SGLT-2 inhibitor)-dapagliflozin (= 52) or empagliflozin (= 32). Renal function was assessed every 3 months for 36 months. Cardiovascular parameters were evaluated every 12 months for 36 months. n n n

RESULTS: Compared with baseline, and systolic blood pressure significantly decreased in both groups (< 0.05). The estimated glomerular filtration rate decreased, but without significance. decreased significantly in both groups and then subsequently increased after 30 months in Group S. Diastolic cardiac function, assessed by E/e' or left atrial volume index, decreased only in Group G at 36 months. p

CONCLUSIONS: The GLP-1 receptor agonist and SGLT-2 inhibitors were effective for glycemic and blood pressure control and for maintaining renal function. The GLP-1 receptor agonist improved diastolic function at 36 months.

Key numbers

0.83%

Decrease in

Average reduction from baseline in both treatment groups after 36 months.

5.8 mmHg

Decrease in systolic blood pressure

Average reduction from baseline in both groups after 36 months.

9.7%

9.7% of patients

In Group G experienced a ≥30% decline in .

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

PubMed

Effects of diabetes drugs on type 2 patients with kidney problems

Abstract

Key numbers

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief